Drug intelligence / Profile preview

KS104

Development stage: Preclinical
Lead developer: Klotho Sciences
Modality: Recombinant Proteins and Enzymes

Overview

KS104 is a Klotho-targeted therapeutic candidate being developed by Klotho Sciences Australia, currently in the IND-enabling phase for the treatment of muscular dystrophy (MD). The drug is part of a pipeline focused on leveraging the biological properties of the Klotho protein, a pleiotropic factor known for its anti-aging, anti-fibrotic, and regenerative effects. KS104 is intended to restore or augment Klotho signaling, which typically declines in degenerative muscle conditions, thereby enhancing muscle repair mechanisms and inhibiting the TGF-beta-mediated fibrotic pathways that contribute to disease progression in MD.

Targets

KL (Klotho Protein)

Beyond the preview

Go deeper on KS104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KS104.

Explore the full profile